Hematology News Editorial Advisory Board
MATT KALAYCIO, M.D., Cleveland Clinic Taussig Cancer Institute
Dr. Kalaycio chairs the department of hematologic oncology and blood disorders at Cleveland Clinic Taussig Cancer Institute, Cleveland. He holds a joint appointment in the clinic's transplant center and is a professor in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Board-certified in hematology and medical oncology, Dr. Kalaycio's clinical interests are in leukemia and stem cell transplantation. In addition to his numerous scientific publications, Dr. Kalaycio has edited a book on leukemia and co-edited a book on clinical malignant hematology.
Dr. Capozzi is associate director of ambulatory services in the department of pharmacy at the Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine in Philadelphia.
Dr. Chanan-Khan chairs the division of hematology/oncology at Mayo Clinic in Jacksonville, Florida. He is a professor of medicine and assistant director for the Center for Individualized Medicine at Mayo. He is a previous chair of the scientific program committee of the American Society of Oncology, and has served on numerous committees for ASCO and the American Society of Hematology. His primary research interest is in experimental therapeutics focused on chronic lymphocytic leukemia (CLL) and multiple myeloma. His expertise is in preclinical target validation and drug evaluation directed towards early phase clinical trials.
Dr. Fischer is professor of medicine and director of the department of hematology and oncology at Otto-von-Guericke-University, Madeburg, Germany. He has published more than 130 articles in clinical science and basic research. His research addresses signal transduction and its therapeutic application in malignant hematology. His current research projects investigate FLT3-ITD signal transduction in acute myeloid leukemia and dysregulation of leukocyte integrins in JAK2-V617F-positive myeloproliferative neoplasia.
Dr. Gupta is an associate professor of medicine at the Princess Margaret Cancer Center in Toronto, Canada. He is the director of the Elizabeth and Tony Comper Myeloproliferative Neoplasms (MPN) Program, and a member of the leukemia group at Princess Margaret, where he also heads up the leukemia fellowship program. His academic interests include genomics and novel therapeutic strategies for MPN. He is the founding member and president of the Canadian MPN Group (mpncanada.com), and a member of the advisory board of Myeloproliferative Disorders - Research Consortium (MPD-RC). He is actively involved in the committee work of the Centre for International Blood and Marrow Transplant Research. He has authored 160 peer-reviewed publications.
Dr. Heslop is the Dan L Duncan Chair and Professor of Medicine and Pediatrics at Baylor College of Medicine, Houston. She also is the interim director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital. She is also associate director for clinical research at the Dan L Duncan Cancer Center. Dr. Heslop is a physician scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. An additional focus is in reconstituting antiviral immunity post-transplant, and she has led an NHLBI-funded multicenter trial of allogeneic multivirus specific T cells. She is the current President of the Foundation for Accreditation of Cell Therapy (FACT) and a past president of the American Society for Blood and Marrow Transplantation.
Dr. Hill is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland. He is on the staff of the bone marrow transplant service and the department of hematology-oncology, and chairs the pharmacy and therapeutics committee at the Taussig Cancer Institute, Cleveland Clinic.
Dr. LeBlanc is an associate professor of medicine in the division of hematologic malignancies and cellular therapy at the Duke University School of Medicine, and director of the Cancer Patient Experience Research Program (CPEP) in the Duke Cancer Institute. He is board-certified in internal medicine, medical oncology, and hospice and palliative medicine, and his practice focuses on the care of patients with blood cancers. Dr. LeBlanc’s program of research focuses on palliative care and patient experience issues in hematology.
Dr. Miller is the director of the Cancer Institute at St. Agnes Hospital in Baltimore, where she has built the program’s research involvement to more than 30 ongoing clinical trials. Her area of expertise is in CML, and her early research at John Hopkins focused on imatinib mesylate. Dr. Miller founded the Baltimore Blood Club, and works to educate community physicians and patients in collaborations with the American Society of Hematology and the Leukemia & Lymphoma Society, which named her their 2008 National Woman of the Year.
Dr. Osunkwo is the medical director for the sickle cell program at the Levine Cancer Institute, Carolinas Healthcare Systems, Charlotte, NC. Dr. Osunkwo is a member of the National Adult Sickle Cell Provider Network and leads the Transition/Medical Home Committee for the South Eastern Regional Genetics Collaborative. Her interests include health literacy, adolescent transition and chronic pain management.
Dr Sosa is an Assistant Professor of Medicine in the section of Hematology and Oncology at Baylor College of Medicine. She received her MD/PhD at the University of Minnesota in Minneapolis and completed her clinical training in internal medicine and hematology at Vanderbilt University. Her research interests are in the field of thrombosis, with a specific emphasis in the role of platelet activation in disease. In collaboration with John Oates’ lab at Vanderbilt, she has developed novel and robust biomarkers to assess platelet activation in vivo in diseases characterized by high risk of thrombosis. She is utilizing these markers of thrombosis to facilitate clinical investigations of human diseases in which platelets are pivotal contributors, with the overall goal of improving the effectiveness of anti-platelet therapy, characterizing platelet dysfunction as an important phenotype for prospective epidemiological studies, and informing the individualization of anti-platelet therapy. Additionally, she is interested in the role of platelet activation in the hematogenous dissemination of tumor cells. She is studying the role of platelet modulation of COX-2 and prostaglandin E2 production by solid tumor adenocarcinomas, with a specific emphasis on the role of aspirin therapy in prevention of metastatic spread.
Dr. Viny is an Instructor in the Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York. He is on the staff of the leukemia service and a clinical researcher in The Ross Levine Lab He received his medical degree from Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. he completed his medical residency at New York Presbyterian/Weill Cornell Medical College and Hematology and Medical Oncology Fellowships at Memorial Sloan Kettering. He is a member of the American Society of Hematology and American Association for Cancer Research and is a Damon Runyon Cancer Research Foundation Postdoctoral Fellow. He is interested in epigenetic modifiers and chromatin dynamics in hematopoietic differentiation and leukemogenesis, with a specific focus on cohesin and DNA-looping interactions.
Dr. Yurkiewicz is a fellow in hematology and oncology at Stanford University, where she also completed her internal medicine residency. Dr. Yurkiewicz holds an M.D. from Harvard Medical School and a B.S. from Yale University. She is interested in hematological malignancies, and her research interests are in clinical trials and outcomes work investigating novel approaches to acute leukemia. Dr. Yurkiewicz also splits her time as a medical writer. During medical school, she created and wrote a blog column at Scientific American on the experiences of a trainee, and her writing has also appeared in The New England Journal of Medicine, Health Affairs, STAT, Aeon Magazine, Science Progress, The News & Observer, and The Best Science Writing Online. She now writes the monthly column “Hard Questions” for Hematology News.
JEFFREY ALLAN ZONDER, M.D., is Professor in the Departments of Oncology at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine. He is the leader of the KCI Myeloma Multidisciplinary sub-team, Medical Director for Karmanos Cancer Center Therapeutic Apheresis Unit, a medical advisor for the Amyloidosis Support Group Networks, and a member of the International Myeloma Working Group, the International Myeloma Society and the International Amyloidosis Society. He received his medical degree from Wayne State University School of Medicine. He completed his medical residency at the University of Rochester in Rochester, New York, before returning to Wayne State University for Hematology-Oncology fellowship training. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, the American Medical Association and the SWOG Barlogie-Salmon Myeloma Committee. He was the national principal investigator of the SWOG study S0232, a randomized trial that helped establish the efficacy of lenalidomide and dexamethasone as initial treatment for myeloma. Dr. Zonder has authored or co-authored numerous original research papers, review articles, book chapters, and research abstracts on myeloma and amyloidosis.